Chemoresistance in Pancreatic Cancer.

Zeng S, Pöttler M, Lan B, Lan B, Grützmann R, Pilarsky C, Yang H. · 2019

Read Chemoresistance in Pancreatic Cancer. by Zeng S, Pöttler M, Lan B, Lan B, Grützmann R, Pilarsky C, Yang H. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6770382.txt.

Introduction

Zeng and co-authors review chemoresistance in pancreatic cancer. Pancreatic ductal adenocarcinoma ranks fourth among cancer killers in the Western world. Late diagnosis, early spread, and weak response to treatment keep death rates high. Surgery plus chemotherapy suits early cases. Strong drug combinations have improved outlooks for advanced disease, yet resistance still cuts them short.

Resistance grows from teamwork among cancer cells, cancer stem cells, and the tumor's surroundings. The review focuses on gemcitabine, a backbone drug. It covers how the drug is processed, how it acts, and the enzymes that blunt it. One enzyme, dCK, is essential for activating gemcitabine, and its levels shift during treatment. Precision drugs may help more patients beat resistance.

Catalog record

CREATORZeng S, Pöttler M, Lan B, Lan B, Grützmann R, Pilarsky C, Yang H.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE75 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6770382

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Chemoresistance in Pancreatic Cancer By Siyuan Zeng, Marina Pöttler, Bin Lan, Robert Grützmann, Christian Pilarsky, Hai Yang Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms20184504 ABSTRACT Abstract Pancreatic ductal adenocarcinoma (PDAC), generally known as pancreatic cancer (PC), ranks the fourth leading cause of cancer-related deaths in the western world. While the incidence of pancreatic cancer is displaying a rising tendency every year, the mortality rate has not decreased significantly because of late diagnosis, early metastasis, and limited reaction to chemotherapy or radiotherapy. Adjuvant chemotherapy after surgical resection is typically the preferred option to treat early pancreatic cancer. Although 5-fluorouracil/leucovorin with irinotecan and oxaliplatin (FOLFIRINOX) and gemcitabine/nab-paclitaxel can profoundly improve the prognosis of advanced pancreatic cancer, the development of chemoresistance still leads to poor clinical outcomes. Chemoresistance is multifactorial as a result of the interaction among pancreatic cancer cells, cancer stem cells, and the tumor microenvironment. Nevertheless, more pancreatic cancer patients will benefit from precision treatment and targeted drugs. Therefore, we outline new perspectives for enhancing the efficacy of gemcitabine after reviewing the related factors of gemcitabine metabolism, mechanism of action, and chemoresistance. Keywords: pancreatic cancer, PDAC, FOLFIRINOX, gemcitabine, chemoresistance 1. INTRODUCTION Ranking as the fourth leading cause of cancer-related mortality in western countries, pancreatic cancer is predicted to become the second leading cause of cancer-related death after lung cancer by 2030 [1]. Pancreatic cancer remains a deadly malignancy, with few symptoms showing before the disease reaches its advanced stage [2]. According to reports, globally, 458,918 new cases of pancreatic cancer were found in 2018, causing 432,242 deaths [3]. Despite progress in the techniques of detecting and managing pancreatic cancer, the five-year survival rate only reaches to about 9% [3,4]. Approximately 90% of pancreatic malignancies are pancreatic ductal adenocarcinomas (PDACs). The primary risk factors related to pancreatic cancer involve smoking, alcohol abuse, diabetes mellitus, obesity, aging, family history, and genetic factors [3,5]. The main factors like low rate of early detection, rapid progression, the development of drug resistance, and lack of proper therapy lead to a poor prognosis of PC. Most primary pancreatic cancer patients lack corresponding clinical symptoms, and the existing screening biomarkers, such as CA19-9, have shown low sensitivity and specificity in diagnosing PC. [6,7] 2. CURRENT TREATMENT OPTIONS OF PANCREATIC CANCER AND LIMITATIONS The current standard of care for resectable pancreatic ductal adenocarcinoma (PDAC) is surgery first followed by adjuvant chemotherapy [8]. However, because of a lack of appropriate early detection and screening methods, most pancreatic cancer patients are diagnosed with advanced or metastatic disease. Only 15% to 20% patients with pancreatic cancer are surgically treated when they are diagnosed, even among patients who have received surgical resections, because most patients will suffer from disease recurrence within a year [9]. The fundamental reasons for these frustrating outcomes are related to poor therapeutic results as an adjuvant surgical treatment, undetected micrometastasis, and the development of chemical resistance. In the last decade, gemcitabine has been considered as the standard treatment and been widely utilized as a first-line drug for advanced pancreatic cancer [10]. The median overall survival rate (5.65 vs. 4.41 months) and one-year survival rate (18% vs. 2%) for gemcitabine-treated patients was significantly improved compared with 5-fluorouracil (5-FU) [10]. Notably, the clinical efficacy response of gemcitabine showed satisfying outcomes, approximately five times that of 5-FU (23.8% vs. 4.8%). Two combination regimens for metastatic pancreatic cancer turned out to be gold standards in recent years: 5-fluorouracil (5-FU)/leucovorin with irinotecan and oxaliplatin (FOLFIRINOX) [11], and gemcitabine with nab-paclitaxel since 2011 [12,13,14]. Several trials have been conducted to test the efficacy of different drugs, either alone or in combination with gemcitabine, and eventually achieved modest success. A recent study showed that adjuvant therapy with a modified FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and fluorouracil) regimen brought a profoundly longer survival than gemcitabine among resected pancreatic cancer patients [15]. The median disease-free survival (DFS) was significantly higher in the modified-FOLFIRINOX group compared with the gemcitabine group (21.6 vs. 12.8 months). The median overall survival (OS) in the modified-FOLFIRINOX group was 54.4 months and 35.0 months in the gemcitabine group. 3. CHEMORESISTANCE IN PANCREATIC CANCER Although gemcitabine and other therapeutic drugs are effective among patients with advanced and metastatic PC, development of chemoresistance to gemcitabine severely limits the effectiveness of this chemotherapy. It is undeniable that pancreatic cancer cells are more resistant to gemcitabine than other chemotherapeutic drugs. Since research on the effects of other drugs is still in its infancy, most studies on chemoresistance in advanced PC have focused on gemcitabine. The underlying mechanism for the development of gemcitabine resistance remains unclear. Various transcription factors, such as enzymes and signaling pathways, involved in nucleoside metabolism are more or less included in the development of chemoresistance to gemcitabine [16,17,18]. 4. MECHANISM OF ACTION OF GEMCITABINE Gemcitabine, also known as dFdC: 2′,2′-difluoro-2′-deoxycytidine (dFdC) (Figure 1), is a deoxycytidine nucleoside analog whose function is mainly dependent on several inhibitions of DNA synthesis [19], thereby inhibiting proliferation and blocking the cell cycle process at the G1/S phase boundary [20]. [Figure: Gemcitabine molecular formula and structure.] Gemcitabine requires intracellular phosphorylation to function after uptake, and its activation and transport are governed by various enzymes [21]. Therefore, nucleoside transport activity is a prerequisite for inhibiting cell growth. This hydrophilic molecule can be transported into cells through a variety of human nucleoside transporters (NTs), including sodium-dependent (concentrative nucleoside transporter hCNTs) and sodium-independent (equilibrative nucleoside transporter hENTs) transporters [22]. The intracellular uptake of dFdC is mainly mediated by hENT1, while the hCNTs family mediates the unidirectional transport of nucleosides into cells. [19]. The cytotoxic activity of gemcitabine may be the result of multiple effects of DNA synthesis. Gemcitabine was phosphorylated into gemcitabine monophosphate (dFdCMP) by deoxycytidine kinase (dCK) after an influx of nucleoside transporters into cell membranes, which underwent complex intracellular transformation to gemcitabine diphosphate (dFdCDP) and triphosphate (dFdCTP), responsible for its cytotoxicity. DNA polymerase can be inhibited by competition with dFdCTP and deoxycytidine triphosphate (dCTP). The effective inhibitor of ribonucleoside reductase, dFdCDP, can lead to depletion of the deoxyribonucleotide pools, which are necessary for DNA synthesis, thereby further enhancing the action of dFdCTP. The dFdCTP is incorporated into the DNA, and after incorporation of another nucleotide, the DNA strand is terminated. This process of “masked chain termination” can hide dFdCTP from DNA repair enzymes and lock gemcitabine into DNA, which leads to the failure of normal DNA repair mechanisms. [19]. Gemcitabine also possesses a unique mechanism to enhance its own activation, termed “self-potentiation”. This “self-potentiation” prolongs the maintenance of high intracellular concentrations of gemcitabine metabolites and increase, which prolongs the maintenance of high intracellular concentrations of gemcitabine metabolites and increases the probability of successful incorporation of gemcitabine into nucleic acids, mainly DNA, by reducing competing natural metabolites [21]. Gemcitabine metabolite dFdCDP potently inhibits ribonucleotide reductase (RR), resulting in a decrease of competing deoxyribonucleotide pools necessary for DNA synthesis [21,23]. Additionally, the intracellular decrease of dFdCTP and dCTP inhibited the inactivation of dCTD to dFdCMP, and the activity required an adequate level of active dCTP [19,21] (Figure 2). [Figure: Mechanism of action of gemcitabine. Gemcitabine activation and transport are governed by various enzymes. Nucleoside transporters include the human concentrative nucleoside transporters (hCNTs) and human equilibrative nucleoside transporters (hENTs). After gemcitabine enters the

Read the complete text